Brokers Set Expectations for Immutep Limited’s FY2025 Earnings (NASDAQ:IMMP)

Immutep Limited (NASDAQ:IMMPGet Rating) – Equities research analysts at Jefferies Financial Group issued their FY2025 earnings per share (EPS) estimates for shares of Immutep in a report issued on Wednesday, August 31st. Jefferies Financial Group analyst D. Stanton anticipates that the biotechnology company will earn ($0.42) per share for the year. The consensus estimate for Immutep’s current full-year earnings is ($0.28) per share.

Immutep Stock Performance

Shares of IMMP stock opened at $1.91 on Friday. Immutep has a twelve month low of $1.80 and a twelve month high of $5.00. The business has a fifty day simple moving average of $2.14 and a 200 day simple moving average of $2.43.

Hedge Funds Weigh In On Immutep

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Millennium Management LLC increased its holdings in Immutep by 3.6% in the 2nd quarter. Millennium Management LLC now owns 1,116,428 shares of the biotechnology company’s stock worth $2,266,000 after purchasing an additional 39,299 shares in the last quarter. Walker Asset Management LLC acquired a new position in Immutep in the 2nd quarter worth about $153,000. Trellus Management Company LLC acquired a new position in Immutep in the 2nd quarter worth about $205,000. Bank of America Corp DE increased its holdings in Immutep by 225.4% in the 1st quarter. Bank of America Corp DE now owns 31,390 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 21,743 shares in the last quarter. Finally, Dimensional Fund Advisors LP acquired a new position in Immutep in the 1st quarter worth about $80,000. Institutional investors and hedge funds own 6.47% of the company’s stock.

Immutep Company Profile

(Get Rating)

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer.

Recommended Stories

Receive News & Ratings for Immutep Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immutep and related companies with MarketBeat.com's FREE daily email newsletter.